Rigel Pharmaceuticals, Inc. (RIGL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.67+0.10 (+2.80%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close3.57
Bid3.62 x 300
Ask3.69 x 2700
Day's Range3.52 - 3.70
52wk Range1.88 - 4.06
1y Target EstN/A
Market Cap347.14M
P/E Ratio (ttm)-6.57
Avg Vol (3m)2,009,217
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Here’s Why These Stocks Are Trending Today
    Insider Monkey16 days ago

    Here’s Why These Stocks Are Trending Today

    The US stock market opened higher today as investors digested a series of economic data, which is being closely watched ahead of the Federal Reserve’s FOMC meeting next week. On the labor market front, a report showed that weekly initial jobless claims were 260,000, slightly below the consensus forecast of 265,000. Apart from the labor market data, […]

  • MarketWatch16 days ago

    Rigel Pharmaceuticals cuts 38% of workforce to refocus on fostamatinib

    Rigel Pharmaceuticals Inc. said Thursday it is cutting 46 jobs, or 38% of its workforce, as it restructures to focus its efforts on commercializing fostamatinib, a treatment for chronic immune thrombocytopenia ...

  • PR Newswire16 days ago

    Rigel Restructures to Focus on Fostamatinib Commercialization

    SOUTH SAN FRANCISCO, Calif., Sept. 15, 2016 /PRNewswire/ -- Rigel Pharmaceuticals (RIGL) today announced plans to build a commercial organization to support the potential launch of fostamatinib, its oral SYK inhibitor, for the treatment of chronic immune thrombocytopenia (ITP). Rigel has reduced its workforce by 38%, resulting in the elimination of 46 positions, mostly in the research area. A smaller research department will continue Rigel's mission to identify and develop novel small molecule therapeutics and will maintain active programs in immunology and oncology.